Literature DB >> 29221253

Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.

Fernando Franco1, David Pérez-Callejo1, Mariano Provencio1.   

Abstract

Entities:  

Year:  2017        PMID： 29221253      PMCID： PMC5708490          DOI： 10.21037/jtd.2017.08.113

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

Review 1.  Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.

Authors:  D De Ruysscher; J Vansteenkiste
Journal:  Radiother Oncol       Date:  2000-04       Impact factor: 6.280

2.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

Authors:  J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

3.  Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

Authors:  Hiroshi Saito; Yoshiki Takada; Yukito Ichinose; Kenji Eguchi; Shinzoh Kudoh; Kaoru Matsui; Kazuhiko Nakagawa; Minoru Takada; Shunichi Negoro; Kenji Tamura; Masahiko Ando; Takuhito Tada; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

Review 4.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Authors:  Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

5.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Authors:  Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

Review 6.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

Authors:  Antonio Rossi; Massimo Di Maio; Paolo Chiodini; Robin Michael Rudd; Hiroaki Okamoto; Dimosthenis Vasilios Skarlos; Martin Früh; Wendi Qian; Tomohide Tamura; Epaminondas Samantas; Taro Shibata; Francesco Perrone; Ciro Gallo; Cesare Gridelli; Olga Martelli; Siow-Ming Lee
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

7.  Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study.

Authors:  Nasser Hanna; Rafat Ansari; William Fisher; Jianzhao Shen; Sin Ho Jung; Alan Sandler
Journal:  Lung Cancer       Date:  2002-03       Impact factor: 5.705

8.  Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer.

Authors:  Shervin M Shirvani; Ritsuko Komaki; John V Heymach; Frank V Fossella; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

9.  Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

Authors:  Ji-Youn Han; Kwan Ho Cho; Dae Ho Lee; Hyae Young Kim; Eun-A Kim; Sung Young Lee; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

10.  Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

Authors:  P A Kosmidis; E Samantas; G Fountzilas; N Pavlidis; F Apostolopoulou; D Skarlos
Journal:  Semin Oncol       Date:  1994-06       Impact factor: 4.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.